Mesoblast products,once approved and integrated in an accepting health system, will remain mostly the same
We are treating the body responses which mostly are known
Pharma developing vaccines have massive costs every time there is a new viral mutation or new pathogen
MSB treat the human body’s immune overeaction and at the same time the patient will develop natural immunity to the pathogen
Pharma are “tricking” an in Vivo response in everybody whether we need it or not.
I know which process I would prefer if our products were freely available.
Just my opinion and happy for opposing opinions❤️☮️
- Forums
- ASX - By Stock
- Moderna
Mesoblast products,once approved and integrated in an accepting...
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
94.5¢ |
Change
0.020(2.16%) |
Mkt cap ! $1.084B |
Open | High | Low | Value | Volume |
94.0¢ | 96.8¢ | 93.5¢ | $4.014M | 4.214M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 19312 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
85.5¢ | 1 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 19312 | 1.010 |
2 | 4061 | 0.995 |
2 | 46987 | 0.990 |
7 | 3700 | 0.970 |
3 | 2845 | 0.960 |
Price($) | Vol. | No. |
---|---|---|
0.855 | 1 | 1 |
0.895 | 30325 | 5 |
0.900 | 29331 | 4 |
0.910 | 2737 | 1 |
0.915 | 17240 | 1 |
Last trade - 15.59pm 09/08/2024 (20 minute delay) ? |
Featured News
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
MSB (ASX) Chart |